Enzo Biochem, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
In the above press release, the company presented results of a preclinical study in an animal model system evaluating one of the Company’s new immune modulatory agents, glucosylceramide (GC), as a potential therapeutic for treating immune mediated diseases.
Enzo Biochem, Inc. engages in the research, development, and market of pharmaceutical products. Its medicines target the following conditions: inflammatory bowel disease, uveitis, human immunodeficiency virus, diabetes, and bone disorders. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY. [Source: MarketWatch]
Company Website: http://www.enzo.com